Tandem-Cleavage Linkers Improve the In Vivo Stability and Tolerability of Antibody–Drug Conjugates
Open accessPublished version of a preprint
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Although peptide motifs represent the majority of cleavable linkers used in clinical-stage antibody-drug conjugates (ADCs), the sequences are often sensitive to cleavage by extracellular enzymes, such as elastase, which leads to systemic release of the cytotoxic payload. This action reduces the therapeutic index by causing off-target toxicities that can be dose-limiting. For example, a common side-effect of ADCs made using peptide-cleavable linkers is myelosuppression, including neutropenia. Only a few reports describe methods for optimizing peptide linkers to maintain efficient and potent tumor payload delivery while enhancing circulating stability. Herein, we address these critical limitations through the development of a tandem-cleavage linker strategy, where two sequential enzymatic cleavage events mediate payload release. We prepared dipeptides that are protected from degradation in the circulation by a sterically encumbering glucuronide moiety. Upon ADC internalization and lysosomal degradation, the monosaccharide is removed and the exposed dipeptide is degraded, which liberates the attached payload inside the target cell. We used CD79b-targeted monomethyl auristatin E (MMAE) conjugates as our model system and compared the stability, efficacy, and tolerability of ADCs made with tandem-cleavage linkers to ADCs made using standard technology with the vedotin linker. The results, where rat studies showed dramatically improved tolerability in the hematopoietic compartment, highlight the role that linker stability plays in efficacy and tolerability and also offer a means of improving an ADC's therapeutic index for improved patient outcomes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Strategies and challenges for the next generation of antibody–drug conjugates
Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.268 · Cited by 2,271
Ogitani, Y., Aida, T., Hagihara, K., Yamaguchi, J., Ishii, C., Harada, N., Soma, M., Okamoto, H., Oitate, M., Arakawa, S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2822 · Cited by 1,177
Challita-Eid, P. M., Satpayev, D., Yang, P., An, Z., Morrison, K., Shostak, Y., Raitano, A., Nadell, R., Liu, W., Lortie, D. R., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1313 · Cited by 724
Dubowchik, G. M., Firestone, R. A., Padilla, L., Willner, D., Hofstead, S. J., Mosure, K., Knipe, J. O., Lasch, S. J., & Trail, P. A. (2002) · Bioconjugate Chemistry · doi:10.1021/bc025536j · Cited by 555
Donaghy, H. (2016) · mAbs · doi:10.1080/19420862.2016.1156829 · Cited by 495
Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads
Masters, J. C., Nickens, D. J., Xuan, D., Shazer, R. L., & Amantea, M. (2018) · Investigational New Drugs · doi:10.1007/s10637-017-0520-6 · Cited by 296
Polson, A. G., Calemine-Fenaux, J., Chan, P., Chang, W., Christensen, E., Clark, S., de Sauvage, F. J., Eaton, D., Elkins, K., Elliott, J. M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2250 · Cited by 252
Site-specific chemical protein conjugation using genetically encoded aldehyde tags
Rabuka, D., Rush, J. S., deHart, G. W., Wu, P., & Bertozzi, C. R. (2012) · Nature Protocols · doi:10.1038/nprot.2012.045 · Cited by 246
Self-citationAnami, Y., Yamazaki, C. M., Xiong, W., Gui, X., Zhang, N., An, Z., & Tsuchikama, K. (2018) · Nature Communications · doi:10.1038/s41467-018-04982-3 · Cited by 226
Polatuzumab Vedotin: First Global Approval
Deeks, E. D. (2019) · Drugs · doi:10.1007/s40265-019-01175-0 · Cited by 221
Dorywalska, M., Dushin, R., Moine, L., Farias, S. E., Zhou, D., Navaratnam, T., Lui, V., Hasa-Moreno, A., Casas, M. G., Tran, T.-T., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-1004 · Cited by 216
Drake, P. M., Albers, A. E., Baker, J., Banas, S., Barfield, R. M., Bhat, A. S., de Hart, G. W., Garofalo, A. W., Holder, P., Jones, L. C., et al. (2014) · Bioconjugate Chemistry · doi:10.1021/bc500189z · Cited by 212
Self-citationDevelopment and Properties of β-Glucuronide Linkers for Monoclonal Antibody−Drug Conjugates
Jeffrey, S. C., Andreyka, J. B., Bernhardt, S. X., Kissler, K. M., Kline, T., Lenox, J. S., Moser, R. F., Nguyen, M. T., Okeley, N. M., Stone, I. J., et al. (2006) · Bioconjugate Chemistry · doi:10.1021/bc0600214 · Cited by 181
Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma
Polson, A. G., Yu, S.-F., Elkins, K., Zheng, B., Clark, S., Ingle, G. S., Slaga, D. S., Giere, L., Du, C., Tan, C., et al. (2007) · Blood · doi:10.1182/blood-2007-01-066704 · Cited by 173
Effect of Attachment Site on Stability of Cleavable Antibody Drug Conjugates
Dorywalska, M., Strop, P., Witt, J. M., Hasa-Moreno, A., Farias, S., Casas, M. G., Delaria, K., Lui, V., Poulsen, K., Loo, C., et al. (2015) · Bioconjugate Chemistry · doi:10.1021/bc5005747 · Cited by 165
Agarwal, P., Kudirka, R., Albers, A. E., Barfield, R. M., de Hart, G. W., Drake, P. M., Jones, L. C., & Rabuka, D. (2013) · Bioconjugate Chemistry · doi:10.1021/bc400042a · Cited by 160
Self-citationBeta-Glucuronidase-Mediated Drug Release
Graaf, M., Boven, E., Scheeren, H., Haisma, H., & Pinedo, H. (2002) · Current Pharmaceutical Design · doi:10.2174/1381612023394485 · Cited by 158
Deng, C., Pan, B.-Q., & O’Connor, O. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0290 · Cited by 148
A Potential Mechanism for ADC-Induced Neutropenia: Role of Neutrophils in Their Own Demise
Zhao, H., Gulesserian, S., Malinao, M. C., Ganesan, S. K., Song, J., Chang, M. S., Williams, M. M., Zeng, Z., Mattie, M., Mendelsohn, B. A., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0133 · Cited by 90
Modulating Antibody–Drug Conjugate Payload Metabolism by Conjugation Site and Linker Modification
Su, D., Kozak, K. R., Sadowsky, J., Yu, S., Fourie-O’Donohue, A., Nelson, C., VANDLEN, R. L., Ohri, R. V., Liu, L., Ng, C., et al. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00785 · Cited by 89
CRISPR-Cas9 screens identify regulators of antibody–drug conjugate toxicity
Tsui, C. K., Barfield, R. M., Fischer, C. R., Morgens, D. W., Li, A., Smith, B. A. H., Gray, M. A., Bertozzi, C. R., Rabuka, D., & Bassik, M. C. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0342-2 · Cited by 85
Self-citationDipeptide-based highly potent doxorubicin antibody conjugates
Jeffrey, S. C., Nguyen, M. T., Andreyka, J. B., Meyer, D. L., Doronina, S. O., & Senter, P. D. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.09.081 · Cited by 82
Sulfatase-cleavable linkers for antibody-drug conjugates
Bargh, J. D., Walsh, S. J., Isidro-Llobet, A., Omarjee, S., Carroll, J. S., & Spring, D. R. (2020) · Chemical Science · doi:10.1039/c9sc06410a · Cited by 78
Improved Lysosomal Trafficking Can Modulate the Potency of Antibody Drug Conjugates
DeVay, R. M., Delaria, K., Zhu, G., Holz, C., Foletti, D. L., Sutton, J. E., Bolton, G. L., Dushin, R. G., Bee, C., Pons, J., et al. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00013 · Cited by 73
York, D., Baker, J., Holder, P. G., Jones, L. C., Drake, P. M., Barfield, R. M., Bleck, G. T., & Rabuka, D. (2016) · BMC Biotechnology · doi:10.1186/s12896-016-0254-0 · Cited by 51
Self-citationUbink, R., Dirksen, E. H. C., Rouwette, M., Bos, E. S., Janssen, I., Egging, D. F., Loosveld, E. M., van Achterberg, T. A. E., Berentsen, K., van der Lee, M. M. C., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0329 · Cited by 48
Poudel, Y. B., Chowdari, N. S., Cheng, H. W., Iwuagwu, C. I., King, D., Kotapati, S., Passmore, D., Rampulla, R., Mathur, A., Vite, G. D., et al. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00325 · Cited by 42
Drake, P. M., Carlson, A., McFarland, J. M., Bañas, S., Barfield, R. M., Zmolek, W., Kim, Y. C., Huang, B. C. B., Kudirka, R. A., & Rabuka, D. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0776 · Cited by 27
Self-citationTailored Linker Chemistries for the Efficient and Selective Activation of ADCs with KSPi Payloads
Lerchen, H., Stelte‐Ludwig, B., Sommer, A., Berndt, S., Rebstock, A., Johannes, S., Mahlert, C., Greven, S., Dietz, L., & Jörißen, H. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.0c00357 · Cited by 23
Typical Antibody–Drug Conjugates
Lambert, J. M. (2016) · Wiley eBooks · doi:10.1002/9781119060727.ch1 · Cited by 14
Research works printed but not linked: 1
- Donaghy H., 2016, MAbs, 1
Cited by
Exploring the next generation of antibody–drug conjugates
Tsuchikama, K., Anami, Y., Ha, S. Y. Y., & Yamazaki, C. M. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00850-2 · Cited by 659
Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability
Nguyen, T. D., Bordeau, B. M., & Balthasar, J. P. (2023) · Cancers · doi:10.3390/cancers15030713 · Cited by 441
Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals
Wang, R., Hu, B., Pan, Z., Mo, C., Zhao, X., Liu, G., Hou, P., Cui, Q., Xu, Z., Wang, W., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01704-3 · Cited by 285
Antibody–Drug Conjugates: A Review of Approved Drugs and Their Clinical Level of Evidence
Gogia, P., Ashraf, H., Bhasin, S., & Xu, Y. (2023) · Cancers · doi:10.3390/cancers15153886 · Cited by 181
Exploration of the antibody–drug conjugate clinical landscape
Maecker, H. L., Jonnalagadda, V. S., Bhakta, S., Jammalamadaka, V., & Junutula, J. R. (2023) · mAbs · doi:10.1080/19420862.2023.2229101 · Cited by 176
Metadata
- Authors
- Chuprakov, S., Ogunkoya, A. O., Barfield, R. M., Bauzon, M., Hickle, C., Kim, Y. C., Yeo, D., Zhang, F., Rabuka, D., & Drake, P. M.
- Affiliations
- Catalent (United States) (US)
- Corresponding author
- Drake, Penelope M.
- ORCID
- Venue
- Bioconjugate Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2021-03-09
- Volume
- 32
- Issue
- 4
- Pages
- 746-754
- ISSN
- 1043-1802 (ISSN-L)
- 1520-4812
- OpenAlex
- W3135311043
- Cited by
- 80
- References
- 30
- Citations by year
- 2026: 22 · 2025: 22 · 2024: 15 · 2023: 9 · 2022: 7 · 2021: 5
- FWCI
- 4.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Bioconjugate Chemistry (publishedVersion, cc-by-nc-nd)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Life Sciences › Immunology and Microbiology › Immunology › Toxin Mechanisms and Immunotoxins
- Keywords
- antibody-drug conjugates, cleavable linkers, lysosomal degradation, payload release, CD79b, monomethyl auristatin E, in vivo stability, tolerability, neutropenia, myelosuppression, therapeutic index
- MeSH terms
- Animals, Antineoplastic Agents, Endocytosis, Female, Hydrolysis, Male, Mice, SCID, Mice, Inbred NOD, Rats, Sprague-Dawley, Immunoconjugates, Xenograft Model Antitumor Assays, Mice, Rats, CD79 Antigens, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.